BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.39 --0%
Revenue Growth %: +31.4%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
PGR, OMID, ACI, More
Revenue Growth %: +31.4%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.44, $0.61 better than the analyst estimate of $0.83. Revenue for the quarter came in at $825 million versus the consensus estimate of $760.37 million.
GUIDANCE:
BioMarin Pharma sees FY2025 EPS of $4.40-$4.55, versus the consensus of $4.16. BioMarin Pharma sees FY2025 revenue of $3.12-3.2 billion, versus the consensus of $3.14 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Telefonica S.A. (VIV) to Neutral
- TD Cowen Bullish on Axon Enterprise (AXON) Enterprise Opportunity
- Virtuix becomes official Meta reseller, Omni One orders triple
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
